| Members |
targetComponentId |
| Ara nobilis |
Diopsittaca nobilis (organism) |
| Ara noblis cumanensis |
Diopsittaca nobilis subspecies cumanensis (organism) |
| Arachnia propionica |
Pseudopropionibacterium propionicum (organism) |
| Aratinga guarouba |
Guaruba guarouba (organism) |
| Arcanobacterium bernardiae |
Trueperella bernardiae (organism) |
| argatroban 100 mg/ml, injektionsvätska, lösning, flaska 2,5 ml |
Product containing precisely argatroban 100 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Arhinencephaly |
Holoprosencephaly sequence |
| aripiprazol 7,5 mg/ml, injektionsvätska, lösning, flaska |
Aripiprazole 7.5 mg/mL solution for injection |
| Arizona infection |
Salmonella enterica subspecies arizonae infection (disorder) |
| operation av arm |
Surgical repair of upper extremity |
| Arteriography of unlisted intra-abdominal arteries |
Angiography of artery |
| Arteriography of unlisted site |
Angiography of artery |
| arteriopatisk impotens |
Erectile dysfunction due to arterial disease (disorder) |
| klinisk handläggningsplan för artrit |
Arthritis clinical management plan (record artifact) |
| Arthroascus schoenii |
Saccharomycopsis schoenii (organism) |
| Arthrobacter duodecadis |
Tetrasphaera duodecadis (organism) |
| Arthrobacter flavescens |
Microbacterium flavescens (organism) |
| Arthrobacter siderocapsulatus |
Pseudomonas putida |
| Arthrobacter terregens |
Microbacterium terregens (organism) |
| Arthrobacter tumescens |
Terrabacter tumescens |
| Arthroderma cajetani |
Paraphyton cookei |
| Arthropathy associated with a condition classifiable elsewhere |
Arthropathy associated with another disorder |
| Arthropathy associated with a mycosis, NEC |
Arthropathy associated with a mycosis |
| Arthropathy associated with bacterial disease, NEC |
Arthropathy associated with bacterial disease |
| Arthropathy associated with helminthiasis, NEC |
Arthropathy associated with helminthiasis |
| Arthropathy associated with viral disease, NEC |
Arthropathy associated with viral disease |
| Arthroplasty - action |
Reconstruction - action |
| Arthrotomy of hip |
Hip joint incision |
| Arthrotomy of knee for infection |
Arthrotomy of knee |
| Arthrotomy of knee for infection with drainage |
Arthrotomy of knee with drainage |
| Arthrotomy of knee for infection with exploration |
Arthrotomy of knee with joint exploration |
| Arthrotomy of knee for infection with removal of foreign body |
Arthrotomy of knee |
| artikainhydroklorid 40 mg + adrenalin 10 mikrogram, injektionsvätska, lösning, flaska |
Product containing only articaine and epinephrine in parenteral dose form (medicinal product form) |
| artikainhydroklorid 40 mg/ml + adrenalin (1:200 000), injektionslösning |
Product containing only articaine and epinephrine in parenteral dose form (medicinal product form) |
| Articular cartilage disorder of other site |
Articular cartilage disorder |
| Artificial insemination with sperm washing and capacitation |
Artificial insemination with sperm washing and capacitation |
| askorbinsyra 250 mg, tuggtablett med apelsinsmak |
Product containing precisely ascorbic acid 250 milligram/1 each conventional release chewable tablet (clinical drug) |
| Aseptic necrosis of other specified site, NEC |
Aseptic necrosis |
| biverkning av aserbin |
Adverse reaction to benzoic acid and/or malic acid and/or salicylic acid ester (disorder) |
| Aspartic proteinase |
Aspartic proteinase |
| Aspergillus amstelodami |
Aspergillus montevidensis (organism) |
| Aspergillus hollandicus |
Aspergillus montevidensis (organism) |
| Aspiration of joint |
Arthrocentesis |
| Aspiration of unspecified fluid |
Pulmonary aspiration of fluid |
| acetylsalicylsyra 400 mg + kodein 8 mg, dispergerbar tablett |
Aspirin and codeine only product in oral dose form |
| acetylsalicylsyra 500 mg + kodein 8 mg, dispergerbar tablett |
Aspirin and codeine only product in oral dose form |
| acetylsalicylsyra 227,5 mg, tuggummitablett |
Aspirin only product in oral dose form |
| acetylsalicylsyra 227,5 mg, medicinskt depåtuggummi |
Aspirin only product in oral dose form |
| acetylsalicylsyra 300 mg, dispergerbar tablett |
Product containing precisely aspirin 1.5 milligram/1 milliliter conventional release oral solution (clinical drug) |
| acetylsalicylsyra 300 mg, löslig tablett |
Product containing precisely aspirin 1.5 milligram/1 milliliter conventional release oral solution (clinical drug) |
| acetylsalicylsyra 500 mg, löslig tablett |
Aspirin 2.5 mg/mL oral solution |
| acetylsalicylsyra 800 mg, enterotablett |
Aspirin only product in oral dose form |
| acetylsalicylsyra 800 mg, tablett med modifierad frisättning |
Aspirin only product in oral dose form |
| extrakt av acetylsalicylsyra |
Product containing aspirin (medicinal product) |
| acetylsalicylsyra 500 mg + papaveretum 7,71 mg, dispergerbar tablett |
Aspirin and papaveretum only product |
| bedömning enligt CADL-2 (communication abilities of daily living, second edition) |
Assessment using Communication Activities of Daily Living Second Edition (procedure) |
| bedömning enligt WHO:s verktyg för skattning av frakturrisk, FRAX |
Hip fracture probability assessment using FRAX (fracture risk assessment tool) |
| bedömning enligt WHO:s verktyg för skattning av osteoporotisk frakturrisk, FRAX |
Osteoporotic fracture probability assessment using osteoporotic fracture risk assessment tool (procedure) |
| tillfällig försämring och akutbehandling av astma sedan förra besöket |
Emergency asthma patient visit since last encounter (situation) |
| Asthma causes daytime symptoms 1 to 2 times per month |
Asthma causes daytime symptoms 1 to 2 times per month (finding) |
| Asthma causes daytime symptoms 1 to 2 times per week |
Asthma causes daytime symptoms 1 to 2 times per week (finding) |
| Asthma causes daytime symptoms most days |
Asthma causes daytime symptoms most days (finding) |
| Asthma causes night symptoms 1 to 2 times per month |
Asthma causes night symptoms 1 to 2 times per month (finding) |
| klinisk handläggningsplan för astma |
Asthma clinical management plan |
| Asthma limits walking on the flat |
Asthma limits walking on the flat (finding) |
| astma med status asthmaticus |
Acute severe exacerbation of asthma (disorder) |
| astrocytom |
Astrocytoma |
| Astrovirus |
Family Astroviridae (organism) |
| ataxi samtidig med och orsakad av cerebrotendinös xantomatos |
Ataxia due to cerebrotendinous xanthomatosis |
| Atherosclerosis of other specified arteries |
Atherosclerosis |
| Atorvastatin calcium 10mg tablet |
Atorvastatin (as atorvastatin calcium) 10 mg oral tablet |
| Atorvastatin calcium 20mg tablet |
Atorvastatin (as atorvastatin calcium) 20 mg oral tablet |
| Atorvastatin calcium 40mg tablet |
Atorvastatin (as atorvastatin calcium) 40 mg oral tablet |
| atosiban 7,5 mg/ml, infusionskoncentrat, flaska 5 ml |
Product containing precisely atosiban (as atosiban acetate) 7.5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Atovaquone+proguanil hydrochloride |
Product containing atovaquone and proguanil (medicinal product) |
| atrakuriumbesylat 100 mg/ 10 ml, lösning |
Atracurium besilate 10 mg/mL solution for injection |
| förmaksmyxom med lentiginos |
Carney complex (disorder) |
| Atrophic age-related macular degeneration |
Nonexudative age-related macular degeneration (disorder) |
| Atrophic glossitis |
Atrophy of tongue papillae |
| atropin 2,1 mg + pralidoxim 600 mg, lösning, en autoinjektor |
Product containing only atropine and pralidoxime in parenteral dose form (medicinal product form) |
| Atropine sulfate + edrophonium chloride 0.14mg/10mg injection |
Product containing only atropine and edrophonium (medicinal product) |
| atropinsulfat 0,031 %, ögondroppar |
Product containing precisely atropine sulfate 310 microgram/1 milliliter conventional release eye solution (clinical drug) |
| atropinsulfat 0,062 %, ögondroppar |
Atropine sulfate 620 microgram/mL eye solution |
| atropinsulfat 0,1 %, ögondroppar |
Atropine sulfate 1 mg/mL eye solution |
| atropinsulfat 0,25 %, ögondroppar |
Product containing precisely atropine sulfate 2.5 milligram/1 milliliter conventional release eye solution (clinical drug) |
| atropinsulfat 140 mikrogram + edrofoniumklorid 10 mg, injektionsvätska, lösning, flaska |
Product containing only atropine and edrophonium (medicinal product) |
| atropinsulfat 500 mikrogram/5 ml, oral lösning |
Atropine only product in oral dose form |
| atropinsulfat 500 mikrogram/5 ml, sockerfri lösning |
Atropine only product in oral dose form |
| atypisk absensepilepsi |
Atypical absence seizure |
| atypiskt antipsykotiskt medel |
Anti-psychotic agent (substance) |
| Auditory function |
Hearing |
| Aurantimonas altamirensis |
Aureimonas altamirensis (organism) |
| Aureobacterium |
Microbacterium |
| Aureobacterium saperdae |
Microbacterium saperdae (organism) |
| Aureobacterium species |
Microbacterium |
| syndrom med aurikulookulär anomali och läppspalt |
Auricular abnormality, cleft lip, ocular abnormality syndrome |
| autogen transplantation av vaskulariserad benvävnad |
Autogenous vascularised bone |
| Autograft |
Autograft |
| Autoimplant |
Autoimplant |
| autointoxikation |
Intestinal dysbiosis |
| Automobile mechanic |
Motor vehicle mechanic |